BACKGROUND: A proportion of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) displays familial aggregation, known as familial Barrett's esophagus (FBE). Pedigrees and characteristics of EAC in these families have been previously described. AIMS: We aimed to evaluate endoscopic and clinical characteristics of Barrett's esophagus in FBE. METHODS: A cohort of 979 BE patients were retrospectively evaluated for FBE, defined as having a first-degree relative with BE or esophageal cancer, confirmed when possible by interview. FBE and sporadic BE were compared regarding demographic, clinical, and endoscopic characteristics. Potential FBE probands were contacted and interviewed to obtain full family pedigrees. RESULTS: Of 603 BE probands (61.6% of total cohort) with a documented family history, 35 (5.8%) had FBE. There was no difference between FBE and non-FBE probands with regard to BE length (median: 3 cm, IQR 2-5 vs. 3 cm, IQR 1-6 cm, respectively; p = 0.78) or hiatal hernia size (p = 0.90). FBE probands were younger (mean, 58.4 vs. 63.8; p = 0.02) and had a significant association with less-advanced neoplasia (adjusted OR 0.41, 95% CI 0.19-0.90). There was no obvious association between FBE and other malignancies. CONCLUSIONS: There were no differences in endoscopic characteristics between FBE and non-FBE probands. While FBE patients were younger and had less-advanced neoplasia, we speculate that these findings may have been the result of more aggressive screening due to the family history. Further studies are warranted to determine whether familial clustering is due to genetic predisposition to development of BE or to risk of neoplastic progression.
BACKGROUND: A proportion of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) displays familial aggregation, known as familial Barrett's esophagus (FBE). Pedigrees and characteristics of EAC in these families have been previously described. AIMS: We aimed to evaluate endoscopic and clinical characteristics of Barrett's esophagus in FBE. METHODS: A cohort of 979 BE patients were retrospectively evaluated for FBE, defined as having a first-degree relative with BE or esophageal cancer, confirmed when possible by interview. FBE and sporadic BE were compared regarding demographic, clinical, and endoscopic characteristics. Potential FBE probands were contacted and interviewed to obtain full family pedigrees. RESULTS: Of 603 BE probands (61.6% of total cohort) with a documented family history, 35 (5.8%) had FBE. There was no difference between FBE and non-FBE probands with regard to BE length (median: 3 cm, IQR 2-5 vs. 3 cm, IQR 1-6 cm, respectively; p = 0.78) or hiatal hernia size (p = 0.90). FBE probands were younger (mean, 58.4 vs. 63.8; p = 0.02) and had a significant association with less-advanced neoplasia (adjusted OR 0.41, 95% CI 0.19-0.90). There was no obvious association between FBE and other malignancies. CONCLUSIONS: There were no differences in endoscopic characteristics between FBE and non-FBE probands. While FBE patients were younger and had less-advanced neoplasia, we speculate that these findings may have been the result of more aggressive screening due to the family history. Further studies are warranted to determine whether familial clustering is due to genetic predisposition to development of BE or to risk of neoplastic progression.
Authors: C M Drovdlic; K A B Goddard; A Chak; W Brock; L Chessler; J F King; J Richter; G W Falk; D K Johnston; J L Fisher; W M Grady; S Lemeshow; C Eng Journal: J Med Genet Date: 2003-09 Impact factor: 6.318
Authors: Amitabh Chak; Heather Ochs-Balcom; Gary Falk; William M Grady; Margaret Kinnard; Joseph E Willis; Robert Elston; Charis Eng Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-09 Impact factor: 4.254
Authors: Christina J Tofani; Kunjal Gandhi; Joseph Spataro; Joseph Yoo; Megan Murphy; Neena Mohan; Zachary Daitch; Apeksha Shah; Raymond Janowski; Colin Huntley; Nooreen Dabbish; Scott Keith; Robert Coben; Sidney Cohen; David Kastenberg; Anthony Infantolino Journal: United European Gastroenterol J Date: 2018-11-29 Impact factor: 4.623
Authors: Anna M J van Nistelrooij; Winand N M Dinjens; Anja Wagner; Manon C W Spaander; J Jan B van Lanschot; Bas P L Wijnhoven Journal: Gastrointest Tumors Date: 2014-05-09
Authors: A M J van Nistelrooij; R van Marion; W F J van Ijcken; A de Klein; A Wagner; K Biermann; M C W Spaander; J J B van Lanschot; W N M Dinjens; B P L Wijnhoven Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Anna M J van Nistelrooij; Ronald van Marion; Katharina Biermann; Manon C W Spaander; J Jan B van Lanschot; Bas P L Wijnhoven; Winand N M Dinjens Journal: Oncoscience Date: 2016-02-01